NanoViricides Inc. (NNVC)

[JG36]

From http://www.secinfo.com/d12TC3.n1p2g.htm:

If we complete our preclinical studies [Injectable FluCide™ against All Influenzas for Hospitalized Patients] in the next 12~18 months, and also are able to produce clinical batches at the end of this period, we can expect Phase I and Phase II human clinical trials to be completed at the earliest by 2016-2017. Revenues may occur as a result of licensing the drug to another pharmaceutical partner at this stage. After Phase III clinical trials completion, revenues are expected to occur after FDA approval and marketing of the drug. Revenues may occur earlier if Flucide is approved for use in other countries or if the BARDA authority determines that FluCide should be stockpiled in the USG CDC stockpile of drugs for defense against pandemic influenza. If we are successful in partnering the drug with another pharmaceutical Company, we may see revenues much earlier than FDA approval. We anticipate that due to the high priority for our work on Ebola related to the current epidemic, our FluCide project plan may be delayed by an additional 6 to 9 months.

From the same source:

While our cash and cash equivalent balance is sufficient for us to continue our operations through June 30, 2016, it is insufficient to fully execute the Company’s business plan. If the Company is unable to obtain debt or equity financing to meet its cash needs it may have to severely limit, its business plan by reducing the funds it hopes to expend on pre-clinical studies and trials, the establishment of our own laboratory and/or research and development project.

So there we have it. Ebolacide will slow down Flucide development, and another round of share dilution will be required before phase II of Flucide is completed. How far below the pre-split value of $1 a share will the stock be when that dilution occurs?

The bears are proven right over and over again.